ABOUT THIS EPISODE
Dave Johnson’s first pharma job wasn't in a lab. It was in a room, dark and cramped, stacked floor to ceiling with 30 years of decaying discovery chemistry data on every storage medium imaginable.
They called it “the cave.”
A physicist turned data leader, Dave has spent two decades solving the same problem: scientific data is generated for one purpose, poorly captured, and left abandoned.
Now co-founding Dash Bio after years leading data science at Moderna, Dave joins Thomas to make a case the industry would rather not hear: AI pilots keep failing because organizations can't understand their own data or tell whether anything they build improves how they work.
Listen in to hear:
- Why "the cave" is still an accurate description of how most pharma companies manage data
- Why clinical trial numbers mean nothing without the metadata behind them
- How the US needs to treat China’s clinical trial volume as a wake-up call
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Data Science Leaders.
OTHER EPISODES IN THIS PODCAST
What’s next for artificial intelligence in 2025? In this episode, Dr. Kjell Carlsson delivers his annual predictions about the immediate future of AI. From AI becoming the universal corporate scapegoat to the rebranding of generative AI as "agentic AI.” Discover why commercial AI solutions remain s…
AI is transforming financial services and insurance, but rarely in the headline-grabbing ways you might expect. From intelligent process automation to fraud detection and risk management, AI is being embedded across operations, but as AI adoption grows, so do the challenges—cybercrime, rapid techno…
What does the global race for AI look like? How has the US Department of Defense been adopting AI by engaging the private sector? And how should we expect AI policy to shift under the new administration?
In this episode – the last in our series on the future of AI – guest host Joel Meye…
AI is transforming drug discovery and clinical trials, making what was once cutting-edge the new standard. Pharma companies are evolving into tech companies, leveraging AI to revolutionize every phase of drug development.In this episode, Chris McSpiritt, VP of Life Sciences Strategy at Domino, disc…
What does the near term future of Enterprise AI look like? A scramble to get valuable, cost-effective, enterprise-grade AI solutions into production, with rigorous governance at scale. If that sounds like a tall order - that’s because it is! However, large advanced organizations (yes, even outside …
Disclaimer: The podcast and artwork embedded on this page are from Domino Data Lab, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.